×
For best experience we recommend to activate Javascript in your browser.
Recombinant KLKB1 (Lanadelumab Biosimilar) antibody
This Human Monoclonal antibody specifically detects KLKB1 (Lanadelumab Biosimilar) . It exhibits reactivity toward Human.
Catalog No. ABIN7597770
$340.97
$401.14
save $60.17 (-15 %)
Plus shipping costs $50.00, if applicable $20.00 dry ice
1 mg ABIN7598585
100 μg ABIN7597770
1 mg ABIN7598585
100 μg ABIN7597770
Delivery in 12 to 14 Business Days
Quick Overview for Recombinant KLKB1 (Lanadelumab Biosimilar) antibody (ABIN7597770)
Target
KLKB1 (Lanadelumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for KLKB1 (Lanadelumab Biosimilar) antibodies
Human
Clonality
All clonalities for KLKB1 (Lanadelumab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for KLKB1 (Lanadelumab Biosimilar) antibodies
This KLKB1 (Lanadelumab Biosimilar) antibody is un-conjugated
Application
Please inquire
Grade
Research Grade
Product Details anti-KLKB1 (Lanadelumab Biosimilar) Antibody
(hide)
Expression System
Mammalian cells
Purpose
Research Grade Lanadelumab Biosimilar Antibody
Specificity
Plasma prekallikrein, KLK3, Fletcher factor, KLKB1, Kininogenin, Plasma kallikrein, PKK
Purification
Protein A or G purified from cell culture supernatant.
Purity
>95 % by SDS-PAGE.
Isotype
IgG1 kappa
Alternatives
(show)
Application Details
(hide)
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
3.16 mg/mL
Buffer
0.01M PBS, pH 7.4.
Storage
4 °C,-20 °C,-80 °C
Storage Comment
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Expiry Date
12 months
Target Details for KLKB1 (Lanadelumab Biosimilar)
(hide)
Target
KLKB1 (Lanadelumab Biosimilar)
Alternative Name
Lanadelumab Biosimilar
Target Type
Biosimilar
Background
Plasma prekallikrein, KLK3, Fletcher factor, KLKB1, Kininogenin, Plasma kallikrein, PKK
UniProt
P03952
CAS-No
1426055-14-2
Recently viewed
(hide)
Chat with us , powered by LiveChat